Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
3D cell culture is a man-made environment in which cells interact with the surroundings in all three dimensions. Cells grown in 3D cell culture exhibit similar properties of cells found inside living organisms in terms of cellular characteristics and behavior.
The global 3D cell culture market is estimated to account for US$ 16,270.5 Mn in terms of value by the end of 2027.
Global 3D Cell Culture Market: Drivers
High prevalence of cancer is expected to propel growth of the global 3D cell culture market over the forecast period. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.
Moreover, R&D in 3D cell culture is also expected to aid in growth of the global 3D cell culture market. For instance, in August 2020, researchers at Okayama University created a new 3D cell culture model of pancreatic cancer that closely mimics the "fibrotic" tissue characteristically observed in patients.
North America held dominant position in the global 3D cell culture market in 2019, accounting for 38.8% share in terms of volume, followed by Europe and Asia Pacific, respectively.
Figure 1: Global 3D Cell Culture Market Share (%) Value, By Region, 2019
Global 3D Cell Culture Market: Restraints
Lack of consistency in products is expected to hinder growth of the global 3D cell culture market. The lack of consistency between wells and batches of cell culture are the other major barriers in the adoption of 3D cell culture techniques. Researchers face severe problems while inserting scaffold/ECM into microplate wells. This inconsistency in the products reduces the reproducibility of results and, thus, reduces the efficiency of the research. In addition, matrices made from animal tissues may contain unwanted growth factors and viruses, which could adversely affect the cell culture productivity and reproducibility.
Moreover, lack of skilled professionals and budget restrictions for research-related activities is also expected to hinder the market growth.
3D Cell Culture Market Report Coverage
||Market Size in 2019:
||US$ 2,093.7 Mn
|Historical Data for:
||2016 to 2019
||2020 to 2027
|Forecast Period 2020 to 2027 CAGR:
||2027 Value Projection:
||US$ 16,270.5 Mn
- North America: U.S., Canada
- Latin America: Brazil, Argentina, Mexico, Rest of Latin America
- Europe: Germany, U.K., France, Spain, Italy, Russia, Rest of Europe
- Asia Pacific: China, Japan, India, Australia, South Korea, ASEAN, Rest of Asia Pacific
- Middle East: GCC Countries, Israel, Rest of Middle East
- Africa: North Africa, Central Africa, South Africa
- By Technology: Extracellular Matrices or Scaffolds, Bioreactors, Gels, Scaffold-free platforms, Microchips.
- By Application: Research, Drug Discovery, Tissue Engineering, Clinical Applications, Stem Cell Biology.
- By End User: Research Labs & Institutes, Biopharmaceutical Industry, Hospitals and diagnostic centers, Others.
Becton, Dickinson and Company, Lonza Group, Thermo Fisher Scientific, Inc., Corning Incorporated, 3D Biotek LLC, 3D Biomatrix, Inc., Global Cell Solutions, Inc., InSphero AG, Sigma-Aldrich Corporation (a subsidiary of Merck KGaA), and Reinnervate Ltd. (a subsidiary of ReproCELL)
- Increasing prevalence of cancer
- Approval and launch of new products
|Restraints & Challenges:
- Lack of skilled professionals
Global 3D Cell Culture Market: Opportunities
Use of microfluidic technology is expected to offer lucrative growth opportunities for players in the global 3D cell culture market. The microfluidic technology has opened an array of opportunities for the 3D cell culture market by developing a platform that can produce a cell culture model, which mimics human organs. The microfluidic technology has various advantages over the traditional method. Microfluidic devices can generate complex dynamic micro-scale environments that resemble in-vivo environments. It reduces the cost of drug discovery by lowering the requirement of samples and reagents.
Moreover, efficacy of 3D cell culture systems over traditional 2D monolayer systems is also expected to aid in growth of the global 3D cell culture market. For instance, in August 2020, a new paper exploring the application of patient-derived organoids (PDOs) published in the journal PLOS ONE reported that 3D cell culture systems reveal drug efficacy previously undetectable in traditional 2D monolayer systems.
The global 3D cell culture market was valued at US$ 2,093.7 Mn in 2019 and is forecast to reach a value of US$ 16,270.5 Mn by 2027 at a CAGR of 29.1% between 2020 and 2027.
Figure 2: Global 3D Cell Culture Market Value (US$ Mn), 2016 – 2027
Market Trends/Key Takeaways
Increasing adoption of 3D cell culture systems is expected to propel growth of the global 3D cell culture market. For instance, in September 2020, MBC BioLabs added a state-of-the-art Leica THUNDER 3D Assay Imager to provide advanced research microscopy capabilities to their members.
Major players in the global 3D cell culture market are focused on adopting partnership strategies to enhance their market share. For instance, in August 2020, Corning Incorporated entered into a supply agreement with BioSurfaces, LLC, under which Corning will supply its Transwell permeable supports plates to BioSurfaces.
Global 3D Cell Culture Market: Competitive Landscape
Major players operating in the global 3D cell culture market include, Becton, Dickinson and Company, Corning Incorporated, Lonza Group, Thermo Fisher Scientific, Inc., 3D Biotek LLC, 3D Biomatrix, Inc., Global Cell Solutions, Inc., InSphero AG, Sigma-Aldrich Corporation (a subsidiary of Merck KGaA), and Reinnervate Ltd. (a subsidiary of ReproCELL).
Global 3D Cell Culture Market: Key Developments
Major players in the global 3D cell culture market are focused on adopting partnership strategies to enhance their market share. For instance, in June 2020, Lonza Group partnered with the Sweden-based company CELLINK to offer a comprehensive 3-dimensional (3D) bioprinting solution designed to optimize and increase access to complete 3D cell culture workflows.